SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Covetrus Pharmaceutical Holding Company Ltd. (Nasdaq – CVET)

BALA CYNWYD – May 25, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Covetrus Inc. (“Covetrus” or the “Company”) (Nasdaq – CVET) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by funds affiliated with Clayton, Dubilier & Rice (“CD&R”), a global private investment firm, and TPG Capital, the private equity platform of global alternative asset management firm TPG (“TPG”), which will acquire all outstanding shares of Covetrus common stock not already owned by affiliates of CD&R for $21.00 per share in cash, representing an enterprise value of approximately $4 billion.

The investigation concerns whether the Covetrus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether CD&R/TPG are paying too little for the Company.

If you own shares of Covetrus stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.